Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Interest Expense

Cost of servicing the company's debt during the period.

Immunocore Holdings plcNASDAQ: IMCR

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of $2.31M fell 23.6% year over year, ahead of the -34.5% change in trailing-twelve-month interest expense. Sequentially, it fell 24.3% from the prior quarter. Over 3 fiscal years it compounded at +31.0% a year.

Context

  • Interest expense amounted to 4.1% of revenue in FY2025, down 3.5 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -23.6% holds above the trailing-twelve-month pace of -34.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.31M-24.3% QoQ
Last fiscal yearDec 2025
$12.17M-35.4% YoY
LTMMar 2026
$11.49M-34.5% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.6%——
1 year-35.4%——
3-year CAGR+31.0%——
5-year CAGR——
10-year CAGR——

Interest Expense history

Mixed currencies · from the income statement

Latest · FY2025
12.17M USD
Year-over-year change
-35.4%

Interest Expense vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -34.5% is the 8th highest of 9, against a peer median of -8.0%.
  • Interest expense amounts to 3.0% of revenue for IMCR, versus a peer median of 5.5%.
IMCR Competitors
Interest Expense for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBRXImmunityBio, Inc.LTM Sep 2026$87.69M USD-12.5%+33.6%48.0%
XNCRXencor, Inc.LTM Jun 2026$27.07M USD-47.6%—25.8%
RCUSArcus Biosciences, Inc.LTM Jun 2026$23M USD+283.3%+58.7%19.7%
BNTXBioNTech SELTM Jun 2026€18.8M EUR+27.7%-4.8%0.7%
MGNXMacroGenics, Inc.LTM Mar 2026$13.31M USD+13616.5%—8.5%
IMCRImmunocore Holdings plcLTM Mar 2026$11.49M USD-34.5%+31.0%3.0%
IMTXImmatics N.V.LTM Mar 2026€909K EUR-3.5%-3.0%2.4%
IPHAInnate Pharma S.A.FY2025€440K EUR-22.3%+15.2%15.8%
IMMPImmutep LimitedFY2025A$24.01K AUD-21.5%-36.2%0.5%
JANXJanux Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
CGENCompugen Ltd.LTM Mar 2026$0 USD——0.0%
Peer median (excluding IMCR) —-8.0%+6.1%5.5%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.